Andy

[Andy @OlivenAndy]

@KontraInvest @Doctor_Salomon @investseekers Open label is, of course, a different matter altogether. But yes, we’ll see its full potential next year after PH 3.

[Andy @OlivenAndy]

@KontraInvest @Doctor_Salomon @investseekers Tirzepatide achieved a 20.9 per cent weight loss after 72 weeks. VK2735 achieved 21.7 per cent after just 33 weeks. To be honest, I don’t see any parity there.

[Andy @OlivenAndy]

@semodough That sounds like it's going to be a painful squeeze

[Andy @OlivenAndy]

@doctorcfa @GilaMonstrum @ObsvRetardation @JCanNuSH As well as the ones you mentioned, you’ve also played your part

[Andy @OlivenAndy]

@jasonghong @investseekers Pharmacies initially stocked up their supplies

[Andy @OlivenAndy]

@HatedMoats Do it!

[Andy @OlivenAndy]

@ResearchPulse1 You won't be able to announce anything major at this meeting—at least not before the CMD—that wouldn't be relevant for a press release.
We can stay tuned, but don't expect anything that will affect the stock price.

[Andy @OlivenAndy]

@bioinvestor24 So, have GLP-1s become even more valuable now?

[Andy @OlivenAndy]

@investseekers The article must be wrong. Emmanuel Papadakis is an analyst at Deutsche Bank, and Citi has a price target of 310 DKK with a “neutral” rating. The article seems to be AI-generated garbage.

[Andy @OlivenAndy]

@proactive_x @novonordisk Emmanuel Papadakis is Analyst at Deutsche Bank not Citi. Wtf is this bullshit

[Andy @OlivenAndy]

AlphaValue/Baader lifted its price target to 466 DKK

$NVO

[Andy @OlivenAndy]

@StockwatchDK And meanwhile, Deutsche Bank writes in its downgrade report: • The boost from Medicare prescriptions appears to be limited. What a bunch of clowns $NVO

[Andy @OlivenAndy]

@bioinvestor24 I do not share your view that oral assets will not define the market in the long term. This is currently the only area where Novo is leading, and the data shows that people want the pill.

[Andy @OlivenAndy]

@bioinvestor24 According to its own statements, Novo is going all in on oral treatments. Accordingly, I expect news to focus primarily on this area on 21 September. How far have they got with improving SNAC, and what insights have they gained from the Vivtex partnership?

[Andy @OlivenAndy]

@investseekers So absolutely nothing has changed since the ‘Hold’ rating two days ago.

[Andy @OlivenAndy]

@investseekers They reaffirmed the ‘Hold’ rating just two days ago – are you sure the source can be trusted? It all sounds rather strange.

[Andy @OlivenAndy]

@columvox and two days ago, those idiots reiterated their ‘hold’ rating

[Andy @OlivenAndy]

@ObvsRetardation According to studies, Foundayo is supposed to be even worse in that regard $nvo